| US: Unscheduled Not FDA approved|
N-Phenylacetyl-L-prolylglycine ethyl ester
Noopept (Russian: Ноопепт; GVS-111, N-phenylacetyl--prolylglycine ethyl ester) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. The compound is patented in both the US and Russia.
Technically, Noopept is not a racetam, due to not having a 2-oxo-pyrrolidine skeleton, but is generally grouped together in the same category because it shares similar mechanisms of action with the racetam family, mainly modulation of the acetylcholine system, as well as modulation of AMPA receptors. When compared to traditional racetams, it has been found to be active at 1/1000th of the dose of the prototypical racetam drug, piracetam. Noopept is a prodrug for the endogenous peptide cycloprolylglycine, which means that Noopept isn't active until metabolized into cycloprolylglycine.
Peak plasma noopept concentrations of 13-33 μg/L are reached within one hour after a single 20 mg oral dose. The half-life averages about 1 hour in healthy individuals. It is mainly cleared renally as a series of metabolites produced by amide and ester hydrolysis, deacylation and aromatic hydroxylation. Noopept may be quantitated in biofluids by liquid chromatography with one of several different detection techniques.